Salidroside Inhibits HMGB1 Acetylation and Release through Upregulation of SirT1 during Inflammation

Zhilin Qi, Yao Zhang, Shimei Qi, Liefeng Ling, Lin Gui, Liang Yan, Jun Lv, Qiang LiOxidative 2017 · DOI

TL;DR

This study reveals that salidroside, a compound from Rhodiola rosea, can reduce the release of HMGB1, a key inflammatory molecule, by upregulating the enzyme SirT1. This mechanism involves inhibiting HMGB1 acetylation and its movement out of the cell nucleus, offering a potential therapeutic strategy for inflammatory diseases like sepsis.

What Problem Does This Paper Address?

High-mobility group box 1 (HMGB1) is a protein that, when released from cells into the extracellular space, acts as a potent pro-inflammatory cytokine. This release is a critical event in inflammatory diseases such as sepsis, contributing to tissue damage and the overall inflammatory response. While HMGB1's role is established, the precise molecular mechanisms controlling its release and how natural compounds might intervene are still areas of active research. Previous work by the authors showed salidroside had anti-inflammatory effects by targeting the JAK2-STAT3 pathway, but its specific impact on HMGB1 release and the underlying mechanisms remained unclear. This paper aims to fill that gap by investigating how salidroside affects HMGB1 release and elucidating the molecular pathways involved.

Methods

The researchers employed a multi-pronged approach:

  • In vivo sepsis model: They used a cecal ligation and puncture (CLP) model in rats to induce sepsis. Salidroside was administered to assess its effect on serum HMGB1 levels and lung injury, which was evaluated histologically.
  • In vitro cell culture: The RAW264.7 macrophage cell line was used to study the effects of lipopolysaccharide (LPS), a common inflammatory stimulus, on HMGB1 release.
  • HMGB1 release assays: Enzyme-linked immunosorbent assay (ELISA) was used to quantify HMGB1 levels in cell culture supernatants.
  • Protein localization studies: Western blotting was used to analyze HMGB1 levels in nuclear and cytoplasmic fractions of cells. Laser confocal microscopy provided visual confirmation of HMGB1's movement between the nucleus and cytoplasm.
  • Post-translational modification analysis: Immunoprecipitation (IP) followed by Western blotting was used to detect HMGB1 acetylation and phosphorylation.
  • Signaling pathway investigation: Western blotting was employed to assess the phosphorylation status of AMPK and the expression levels of SirT1.
  • Genetic manipulation: Overexpression and knockdown (shRNA) of SirT1 were performed to directly test its role in HMGB1 regulation and salidroside's effects.

Datasets

Not discussed in the paper. The study relies on experimental data generated from cell cultures and animal models.

Key Insights and Ideas

  • Salidroside as a direct HMGB1 release inhibitor: Beyond its previously identified effects on other inflammatory pathways, salidroside directly reduces HMGB1 release, both in a sepsis model and in LPS-stimulated cells.
  • HMGB1 acetylation is the key target: The study strongly suggests that salidroside's inhibitory effect on HMGB1 release is primarily mediated by reducing HMGB1 acetylation, rather than phosphorylation. This is a crucial distinction as different post-translational modifications can have varied effects on HMGB1's fate.
  • The AMPK-SirT1 axis is central: Salidroside appears to activate the AMPK pathway, which in turn upregulates the expression and activity of SirT1. SirT1, a deacetylase, then acts to reduce HMGB1 acetylation.
  • SirT1's protective role: Overexpressing SirT1 mimicked salidroside's effects by reducing HMGB1 acetylation and translocation. Conversely, knocking down SirT1 diminished salidroside's ability to reverse LPS-induced HMGB1 changes.
  • A unified mechanism: The findings propose a coherent signaling cascade: Salidroside → AMPK activation → SirT1 upregulation → HMGB1 deacetylation → Inhibition of HMGB1 nucleocytoplasmic translocation and release.

Key Results

  • In CLP-induced sepsis in rats, salidroside significantly reduced serum HMGB1 levels and attenuated lung injury.
  • In LPS-stimulated RAW264.7 cells, salidroside dose-dependently inhibited HMGB1 release into the supernatant.
  • Salidroside treatment prevented the LPS-induced translocation of HMGB1 from the nucleus to the cytoplasm.
  • Salidroside specifically inhibited LPS-induced HMGB1 acetylation, with no significant effect on phosphorylation.
  • Salidroside enhanced the expression of SirT1 in a time- and dose-dependent manner, and this effect was observed even in the presence of LPS, which normally reduces SirT1.
  • Salidroside also promoted AMPK phosphorylation, suggesting its action is mediated through this pathway.
  • Overexpression of SirT1 mimicked salidroside's inhibitory effects on HMGB1 acetylation and translocation.
  • Knockdown of SirT1 impaired salidroside's ability to reverse LPS-induced HMGB1 acetylation and translocation, confirming SirT1's essential role.

Limitations and Future Work

  • Direct interaction of SirT1 and HMGB1: While the study strongly implicates SirT1 in deacetylation, the direct physical interaction between SirT1 and HMGB1, and how salidroside might influence this interaction, requires further investigation.
  • In vivo validation of the pathway: While the in vitro studies strongly support the AMPK-SirT1-HMGB1 acetylation pathway, further in vivo experiments could directly confirm these molecular events in the context of sepsis.
  • Therapeutic potential: The authors suggest salidroside could be a potential treatment for diseases where HMGB1 is a target, but clinical translation would require extensive further research.
  • Broader implications: The study provides a new perspective on salidroside's anti-inflammatory function, but its effects on other HMGB1-related inflammatory processes or diseases could be explored.

Summary updated

Abstract

HMGB1, a highly conserved nonhistone DNA-binding protein, plays an important role in inflammatory diseases. Once released to the extracellular space, HMGB1 acts as a proinflammatory cytokine that triggers inflammatory reaction. Our previous study showed that salidroside exerts anti-inflammatory effect via inhibiting the JAK2-STAT3 signalling pathway. However, whether salidroside inhibits the release of HMGB1 is still unclear. In this study, we aim to study the effects of salidroside on HMGB1 release and then investigate the potential molecular mechanisms. In an experimental rat model of sepsis caused by CLP, salidroside administration significantly attenuated lung injury and reduced the serum HMGB1 level. In RAW264.7 cells, we investigated the effects of salidroside on LPS-induced HMGB1 release and then explored the underlying molecular mechanisms. We found that salidroside significantly inhibited LPS-induced HMGB1 release, and the inhibitory effect was correlated with the HMGB1 acetylation levels. Mechanismly, salidroside inhibits HMGB1 acetylation through the AMPK-SirT1 pathway. In addition, SirT1 overexpression attenuated LPS-induced HMGB1 acetylation and nucleocytoplasmic translocation. Furthermore, in SirT1 shRNA plasmid-transfected cells, salidroside treatment enhanced SirT1 expression and reduced LPS-activated HMGB1 acetylation and nucleocytoplasmic translocation. Collectively, these results demonstrated that salidroside might reduce HMGB1 release through the AMPK-SirT1 signalling pathway and suppress HMGB1 acetylation and nucleocytoplasmic translocation.
BibTeX
@inproceedings{qi2017salidroside,
  author = {Zhilin Qi and Yao Zhang and Shimei Qi and Liefeng Ling and Lin Gui and Liang Yan and Jun Lv and Qiang Li},
  title = {{Salidroside Inhibits HMGB1 Acetylation and Release through Upregulation of SirT1 during Inflammation}},
  booktitle = {Oxidative},
  year = {2017},
  doi = {10.1155/2017/9821543},
}
Figure